Tert-butyl 2-icosa-5,8,11,14,17-pentaenoxybutanoate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: Tert-butyl 2-icosa-5,8,11,14,17-pentaenoxybutanoate
• 英文别名: tert-butyl 2-icosa-5,8,11,14,17-pentaenoxybutanoate
• 化学式: C₂₈H₄₆O₃
• 分子量: 430.7
• InChiKey: CHSHEVONIHVWMM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.2
• 重原子数：
  31
• 可旋转键数：
  19
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.61
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• POLYUNSATURATED FATTY ACIDS FOR THE TREATMENT OF DISEASES RELATED TO CARDIOVASCULAR, METABOLIC AND INFLAMMATORY DISEASE AREAS
  申请人：Hovland Ragnar

  公开号：US20120122940A1

  公开（公告）日：2012-05-17

  The present disclosure relates to lipid compounds of the general formula (I): R1-O—C(R2)(R3)-X  (I) wherein R 1 is a C 10 -C 22 alkyl group, a C 10 -C 22 alkenyl group having 1-6 double bonds, or a C 10 -C 22 alkynyl group having 1-6 triple bonds; R 2 and R 3 are the same or different and may be chosen from different substituents; and X is a carboxylic acid or a derivative thereof, such as a carboxylic ester, a carboxylic anhydride, a phospholipid, triglyceride, or a carboxamide; or a pharmaceutically acceptable salt, solvate, solvate of such salt or a prodrug thereof. The present disclosure also relates to pharmaceutical compositions and lipid compositions comprising at least one compound according to the present disclosure, and to such compounds for use as medicaments or for use in therapy, in particular for the treatment of diseases related to the cardiovascular, metabolic, and inflammatory disease area.

  本公开涉及一般式（I）的脂质化合物：R1-O-C（R2）（R3）-X（I），其中R1是C10-C22烷基，具有1-6个双键的C10-C22烯基，或具有1-6个三键的C10-C22炔基；R2和R3相同或不同，可以选择不同的取代基；X是羧酸或其衍生物，例如羧酸酯，羧酸酐，磷脂，甘油三酯或羧酰胺；或药学上可接受的盐，溶剂，该盐的溶剂或其前药。本公开还涉及包含至少一种根据本公开的化合物的制药组合物和脂质组合物，并涉及这些化合物的用途作为药物或用于治疗，特别是用于治疗与心血管，代谢和炎症相关的疾病领域。
• SALICYLATE FATTY ACID DERIVATIVES
  申请人：Hovland Ragnar

  公开号：US20130046013A1

  公开（公告）日：2013-02-21

  Fatty acid conjugates of salicylate derivatives and compositions thereof are disclosed. Further disclosed are methods for treating various diseases comprising the administration of an effective amount of at least one compound according to the present disclosure.

  本文公开了水杨酸衍生物的脂肪酸共轭物及其组合物。进一步公开了治疗各种疾病的方法，包括根据本公开的至少一种化合物的有效量进行给药。
• METHODS OF TREATMENT USING LIPID COMPOUNDS
  申请人：Hovland Ragnar

  公开号：US20130345269A1

  公开（公告）日：2013-12-26

  Methods are disclosed to treat or prevent at least one disease or condition in a subject in need thereof comprising administering a compound of Formula (I): or a pharmaceutically acceptable salt, or ester thereof, wherein R 1 and R 2 are independently chosen from a hydrogen atom or linear, branched, and/or cyclic C 1 -C 6 alkyl groups, with the proviso that R 1 and R 2 are not both hydrogen or a pharmaceutically acceptable salt or ester thereof. Such diseases or conditions may relate to coronary heart disease (CHD), for example atherosclerosis; metabolic syndrome/insulin resistance; and/or a dyslipidemic condition such as hypertriglyceridemia (HTG), elevated LDL-cholesterol, elevated total-cholesterol, elevated Apo B and low HDL-cholesterol. The present disclosure further provides for a method of reducing atherosclerosis development. Pharmaceutical compositions comprising a compound of Formula (I) are also disclosed.

  本文介绍了一种治疗或预防受试者至少一种疾病或病况的方法，包括给予式(I)化合物或其药学上可接受的盐或酯。其中，R1和R2是独立选择的氢原子或线性、支链和/或环状C1-C6烷基，但R1和R2不能同时为氢或其药学上可接受的盐或酯。这些疾病或病况可能涉及冠心病（CHD），例如动脉粥样硬化；代谢综合征/胰岛素抵抗；和/或血脂紊乱症，如高甘油三酯血症（HTG）、升高的LDL胆固醇、升高的总胆固醇、升高的载脂蛋白B和低HDL胆固醇。本文还提供了一种减少动脉粥样硬化发展的方法。同时，本文还揭示了包含式(I)化合物的药物组合物。
• [EN] POLYUNSATURATED FATTY ACIDS FOR THE TREATMENT OF DISEASES RELATED TO CARDIOVASCULAR, METABOLIC AND INFLAMMATORY DISEASE AREAS<br/>[FR] ACIDES GRAS POLYINSATURÉS POUR LE TRAITEMENT DE MALADIES RELATIVES AU DOMAINE DES MALADIES CARDIOVASCULAIRES, MÉTABOLIQUES ET INFLAMMATOIRES.
  申请人：PRONOVA BIOPHARMA NORGE AS

  公开号：WO2010128401A9

  公开（公告）日：2011-12-08
• USE OF THIA OXO COMPOUNDS FOR LOWERING APO C3
  申请人：Pronova Biopharma Norge AS

  公开号：US20180110747A1

  公开（公告）日：2018-04-26

  Methods are disclosed to reduce apolipoprotein C-III (apoC-III) mRNA or protein in a subject in need thereof, comprising administering a pharmaceutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein R 1 and R 2 are independently chosen from a hydrogen atom or linear, branched, and/or cyclic C 1 -C 6 alkyl groups, with the proviso that R 1 and R 2 are not both hydrogen.